Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Net Debt
Total debt minus cash and equivalents; a negative value means the company holds more cash than debt.
Maze Therapeutics, Inc.NASDAQ: MAZE
Net Debt · Q1 FY2026 · quarter ended Mar 2026
Net debt remains negative
Q1 FY2026 net debt was -$137.54M, compared with -$268.55M a year earlier.
Context
- Net debt amounted to 32.8% of total assets at the end of Q1 FY2026, down 47.9 pp from a year earlier.
- Net debt increased in 2 of the last 3 fiscal years.
What to watch
Whether net debt keeps rising in the next quarterly balance sheet after a +48.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Debt history
USD · from the balance sheet
- Latest · FY2025
- (165.94M) USD
- Year-over-year change
- +2.5%
| Period | Period end | Net Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (165.94M) | +2.5% |
| FY2024 | 2024-12-31 | (170.18M) | -931.6% |
| FY2023 | 2023-12-31 | 20.47M | +130.2% |
| FY2022 | 2022-12-31 | (67.86M) | — |
Net Debt vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so net debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +48.8% is the 3rd highest of 8, against a peer median of +42.4%.
- Net debt amounts to 32.8% of total assets for MAZE, versus a peer median of 23.4%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $492.61M USD | +125.1% | -12.0% | 58.1% | |
| Mar 2026 | $177.06M USD | +42.4% | — | 35.1% | |
| Mar 2026 | -$4.66M USD | -104.8% | — | 8.8% | |
| Dec 2025 | -€39.87M EUR | +5.6% | — | 16.0% | |
| Mar 2026 | -$137.54M USD | +48.8% | — | 32.8% | |
SEPNSepterna, Inc. | Sep 2026 | -$145.13M USD | +50.9% | — | 23.4% |
BIOABioAge Labs, Inc. | Mar 2026 | -$237.74M USD | +3.8% | — | 59.8% |
| Jun 2026 | -$353.42M USD | +43.8% | +13.4% | 10.9% | |
| Peer median (excluding MAZE) | — | +42.4% | +0.7% | 23.4% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.